Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorYale University
About this trial
The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in hepatology clinics. There are many benefits of AUD treatment among patients with AUD and ALD such as reduction in liver-related complications and hepatology clinicians providing this care in an integrated fashion can improve access and uptake.
Eligibility criteria
Qualifiers
Must provide care for patients with liver disease at a hepatology clinical location within the Yale School of Medicine and YNHH medical system.
Disqualifiers
Providers who do not treat patients with chronic liver disease and alcohol-associated liver disease.
Trial design
Treatments tested in this trial
- Implementation Intervention
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Yale University
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborator
Source ClinicalTrials.gov